AVITA Medical, Inc.
General ticker "RCEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $196.6M (TTM average)
AVITA Medical, Inc. does not follow the US Stock Market performance with the rate: -21.6%.
Estimated limits based on current volatility of 2.5%: low 3.47$, high 3.65$
Factors to consider:
- Total employees count: 260 as of 2024
- US accounted for 96.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Product recalls, Cybersecurity threats, Market competition, Regulatory and compliance, Economic downturns and volatility
- Current price 45.6% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.52$, 15.71$]
- 2025-12-31 to 2026-12-31 estimated range: [5.70$, 14.04$]
Financial Metrics affecting the RCEL estimates:
- Negative: with PPE of -5.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -15.17 <= 0.33
- Positive: Industry inventory ratio change (median), % of -1.44 <= -0.15
- Positive: Inventory ratio change, % of 0.37 <= 0.84
- Positive: Interest expense per share per price, % of 1.66 <= 3.41
- Positive: Investing cash flow per share per price, % of 11.59 > -0.66
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 5.64 <= 18.93
- Negative: negative Net income
Short-term RCEL quotes
Long-term RCEL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $34.42MM | $51.57MM | $64.25MM |
| Operating Expenses | $61.93MM | $94.23MM | $120.84MM |
| Operating Income | $-27.50MM | $-42.66MM | $-56.59MM |
| Non-Operating Income | $0.88MM | $7.34MM | $-5.20MM |
| Interest Expense | $0.00MM | $1.14MM | $5.36MM |
| R&D Expense | $13.86MM | $20.82MM | $20.36MM |
| Income(Loss) | $-26.63MM | $-35.31MM | $-61.79MM |
| Taxes | $0.04MM | $0.07MM | $0.05MM |
| Profit(Loss)* | $-26.66MM | $-35.38MM | $-61.84MM |
| Stockholders Equity | $84.74MM | $49.06MM | $4.50MM |
| Inventory | $2.12MM | $5.60MM | $7.27MM |
| Assets | $98.26MM | $111.64MM | $79.71MM |
| Operating Cash Flow | $-19.09MM | $-38.01MM | $-48.94MM |
| Capital expenditure | $0.53MM | $1.45MM | $9.33MM |
| Investing Cash Flow | $-19.33MM | $1.61MM | $37.36MM |
| Financing Cash Flow | $0.90MM | $40.37MM | $3.51MM |
| Earnings Per Share** | $-1.07 | $-1.40 | $-2.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.